A PHASE 1, SINGLE-CENTER, OPEN-LABEL STUDY INVESTIGATING THE EXCRETION BALANCE, PHARMACOKINETICS AND METABOLISM OF A SINGLE ORAL DOSE AND PHARMACOKINETICS OF AN INTRAVENOUS TRACER OF [14-C]-RO5424802 IN HEALTHY MALE SUBJECTS
Latest Information Update: 14 Sep 2015
At a glance
- Drugs Alectinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Roche
- 11 May 2015 Status changed from discontinued to completed, as reported by ClinicalTrials.gov.
- 02 Apr 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov
- 09 Mar 2015 Status changed from discontinued to completed as reported by ClinicalTrials.gov